APA (7th ed.) Citation

HE, B., OA, K., L, C., ML, U., RX, S., KR, B., . . . R, R. (2021). Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. The Journal of clinical investigation, 131(7), . https://doi.org/10.1172/JCI142677

Chicago Style (17th ed.) Citation

HE, Burston, et al. "Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer." The Journal of Clinical Investigation 131, no. 7 (2021). https://doi.org/10.1172/JCI142677.

MLA (9th ed.) Citation

HE, Burston, et al. "Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer." The Journal of Clinical Investigation, vol. 131, no. 7, 2021, https://doi.org/10.1172/JCI142677.